Pulmonary Arterial Hypertension Market Research Report by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog), by Distribution (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,570.98 Million in 2020 to USD 9,925.12 Million by the end of 2025.
2. The Global Pulmonary Arterial Hypertension Market is expected to grow from EUR 6,638.38 Million in 2020 to EUR 8,702.54 Million by the end of 2025.
3. The Global Pulmonary Arterial Hypertension Market is expected to grow from GBP 5,901.54 Million in 2020 to GBP 7,736.57 Million by the end of 2025.
4. The Global Pulmonary Arterial Hypertension Market is expected to grow from JPY 808,016.35 Million in 2020 to JPY 1,059,262.87 Million by the end of 2025.
5. The Global Pulmonary Arterial Hypertension Market is expected to grow from AUD 10,994.08 Million in 2020 to AUD 14,412.60 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Pulmonary Arterial Hypertension to forecast the revenues and analyze the trends in each of the following sub-markets:
'The Prostacyclin & Prostacyclin Analog is projected to witness the highest growth during the forecast period'
Based on Drug Class, the Pulmonary Arterial Hypertension Market studied across Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog. The Prostacyclin & Prostacyclin Analog commanded the largest size in the Pulmonary Arterial Hypertension Market in 2020, and it is expected to grow at the fastest CAGR during the forecast period.
'The Online Pharmacy is projected to witness the highest growth during the forecast period'
Based on Distribution, the Pulmonary Arterial Hypertension Market studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy commanded the largest size in the Pulmonary Arterial Hypertension Market in 2020. On the other hand, the Online Pharmacy is expected to grow at the fastest CAGR during the forecast period.
'The Asia-Pacific is projected to witness the highest growth during the forecast period'
Based on Geography, the Pulmonary Arterial Hypertension Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Pulmonary Arterial Hypertension Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Arterial Hypertension Market including Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Arterial Hypertension Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pulmonary Arterial Hypertension Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Arterial Hypertension Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Arterial Hypertension Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Arterial Hypertension Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Arterial Hypertension Market?
6. What are the modes and strategic moves considered suitable for entering the Global Pulmonary Arterial Hypertension Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,570.98 Million in 2020 to USD 9,925.12 Million by the end of 2025.
2. The Global Pulmonary Arterial Hypertension Market is expected to grow from EUR 6,638.38 Million in 2020 to EUR 8,702.54 Million by the end of 2025.
3. The Global Pulmonary Arterial Hypertension Market is expected to grow from GBP 5,901.54 Million in 2020 to GBP 7,736.57 Million by the end of 2025.
4. The Global Pulmonary Arterial Hypertension Market is expected to grow from JPY 808,016.35 Million in 2020 to JPY 1,059,262.87 Million by the end of 2025.
5. The Global Pulmonary Arterial Hypertension Market is expected to grow from AUD 10,994.08 Million in 2020 to AUD 14,412.60 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Pulmonary Arterial Hypertension to forecast the revenues and analyze the trends in each of the following sub-markets:
'The Prostacyclin & Prostacyclin Analog is projected to witness the highest growth during the forecast period'
Based on Drug Class, the Pulmonary Arterial Hypertension Market studied across Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5, and Prostacyclin & Prostacyclin Analog. The Prostacyclin & Prostacyclin Analog commanded the largest size in the Pulmonary Arterial Hypertension Market in 2020, and it is expected to grow at the fastest CAGR during the forecast period.
'The Online Pharmacy is projected to witness the highest growth during the forecast period'
Based on Distribution, the Pulmonary Arterial Hypertension Market studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy commanded the largest size in the Pulmonary Arterial Hypertension Market in 2020. On the other hand, the Online Pharmacy is expected to grow at the fastest CAGR during the forecast period.
'The Asia-Pacific is projected to witness the highest growth during the forecast period'
Based on Geography, the Pulmonary Arterial Hypertension Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Pulmonary Arterial Hypertension Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Arterial Hypertension Market including Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Arterial Hypertension Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pulmonary Arterial Hypertension Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Arterial Hypertension Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Arterial Hypertension Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Arterial Hypertension Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Arterial Hypertension Market?
6. What are the modes and strategic moves considered suitable for entering the Global Pulmonary Arterial Hypertension Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Distribution Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cardiovascular diseases and the growing geriatric population
5.1.1.2. Supportive government initiatives for the development of orphan drugs
5.1.1.3. Clinical drugs in pipeline for pulmonary treatment
5.1.2. Restraints
5.1.2.1. Limited awareness about presence of pulmonary arterial hypertension among patients
5.1.2.2. High diagnosis & treatment cost of pulmonary disorders
5.1.3. Opportunities
5.1.3.1. Advance oral drugs for pulmonary arterial hypertension
5.1.3.2. Technology advancement such as biomaker and new gene therapy for the treatment
5.1.4. Challenges
5.1.4.1. Complicated process of clinical approval of drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS
6.1. Introduction
6.2. Calcium Channel Blocker
6.3. Endothelin Receptor Antagonists
6.4. Phosphodiesterase
6.5. Prostacyclin & Prostacyclin Analog
7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY DISTRIBUTION
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy
8. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Arena Pharmaceuticals
12.2. Bayer AG
12.3. Bristol-Myers Squibb Company
12.4. Gilead Sciences, Inc.
12.5. GlaxoSmithKline Plc
12.6. Johnson & Johnson
12.7. Merck & Co. Inc.
12.8. Novartis International AG
12.9. Pfizer, Inc.
12.10. United Therapeutics Corporation
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Distribution Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cardiovascular diseases and the growing geriatric population
5.1.1.2. Supportive government initiatives for the development of orphan drugs
5.1.1.3. Clinical drugs in pipeline for pulmonary treatment
5.1.2. Restraints
5.1.2.1. Limited awareness about presence of pulmonary arterial hypertension among patients
5.1.2.2. High diagnosis & treatment cost of pulmonary disorders
5.1.3. Opportunities
5.1.3.1. Advance oral drugs for pulmonary arterial hypertension
5.1.3.2. Technology advancement such as biomaker and new gene therapy for the treatment
5.1.4. Challenges
5.1.4.1. Complicated process of clinical approval of drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY DRUG CLASS
6.1. Introduction
6.2. Calcium Channel Blocker
6.3. Endothelin Receptor Antagonists
6.4. Phosphodiesterase
6.5. Prostacyclin & Prostacyclin Analog
7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY DISTRIBUTION
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy
8. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Arena Pharmaceuticals
12.2. Bayer AG
12.3. Bristol-Myers Squibb Company
12.4. Gilead Sciences, Inc.
12.5. GlaxoSmithKline Plc
12.6. Johnson & Johnson
12.7. Merck & Co. Inc.
12.8. Novartis International AG
12.9. Pfizer, Inc.
12.10. United Therapeutics Corporation
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: SCORES
TABLE 73. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: BUSINESS STRATEGY
TABLE 74. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PRODUCT SATISFACTION
TABLE 75. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RANKING
TABLE 76. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MERGER & ACQUISITION
TABLE 77. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 78. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 79. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: INVESTMENT & FUNDING
TABLE 80. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 81. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: SCORES
TABLE 73. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: BUSINESS STRATEGY
TABLE 74. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PRODUCT SATISFACTION
TABLE 75. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RANKING
TABLE 76. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MERGER & ACQUISITION
TABLE 77. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 78. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 79. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: INVESTMENT & FUNDING
TABLE 80. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 81. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (%)
FIGURE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025
FIGURE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, 2020 VS 2025 (USD MILLION)
FIGURE 26. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 27. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 29. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 30. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 31. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 32. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 33. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 34. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 35. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 37. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 44. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 47. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 49. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 61. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 62. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 63. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE
FIGURE 1. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
FIGURE 14. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 16. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ENDOTHELIN RECEPTOR ANTAGONISTS, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PHOSPHODIESTERASE 5, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY PROSTACYCLIN & PROSTACYCLIN ANALOG, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (%)
FIGURE 21. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY DISTRIBUTION, 2025
FIGURE 23. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY HOSPITAL PHARMACY, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY ONLINE PHARMACY, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY RETAIL PHARMACY, 2020 VS 2025 (USD MILLION)
FIGURE 26. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 27. AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 29. ARGENTINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 30. BRAZIL PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 31. CANADA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 32. MEXICO PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 33. UNITED STATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 34. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 35. ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 37. AUSTRALIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. CHINA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. INDIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. INDONESIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. JAPAN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. MALAYSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. PHILIPPINES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 44. SOUTH KOREA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. THAILAND PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 47. EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 49. FRANCE PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. GERMANY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. ITALY PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. NETHERLANDS PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. QATAR PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. RUSSIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. SAUDI ARABIA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. SOUTH AFRICA PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. SPAIN PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. UNITED ARAB EMIRATES PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. UNITED KINGDOM PULMONARY ARTERIAL HYPERTENSION MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 61. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 62. GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 63. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PULMONARY ARTERIAL HYPERTENSION MARKET, BY TYPE
